Antihypertensive effects of some new nitroxyalkyl 1,4-dihydropyridine derivatives in rat model of two-kidney, one-clip hypertension

Iranian Journal of Pharmaceutical Research

Volumn 8, Issue 3, 2009, Pages 193-199

  Nekooeian, Ali Akbar ^a   Khalili, Azadeh ^a   Javidnia, Katayoun ^b,c   Mehdipour, Ahmad Reza ^b   Miri, Ramin ^b,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

1,4 dihydropyridines; MAP; One clip hypertension; Two kidney

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; NIFEDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; EXPERIMENTAL RAT; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; RENOVASCULAR HYPERTENSION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

EID: 73949135799     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Fleckenstein A, Tritthart H, Döring HJ and Byon KY. BAY a 1040 - a highly potent Ca++ -antagonistic inhibitor of electro-mechanical coupling processes in mammalian myocardium. Arzneimittelforschung. (1972) 22: 22-33.
2. Safak C and Simsek R. Fused 1, 4-Dihydropyridines as potential calcium modulatory compounds. Mini Rev. Med. Chem. (2006) 6: 747-55.
3. Epstein BJ, Vogel K and Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs (2007) 67: 1309-27.
4. Meredith PA and Elliot HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J. Hypertens. (2004) 22: 1641-8.
5. Michel T. Treatment of myocardial ischemia. In: Brunton LL, Lazo JS and Parker KL. (eds.) Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed., McGraw-Hill, USA (2006) page no.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitors or calcium channel blockers vs diuretics. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 335: 2981-97.
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet (2000) 355: 1955-64.
8. Miri R, Niknahad H, Vesal G and Shafiee A. Synthesis and calcium channel antagonist activities of 3-nitrooxyalkyl, 5-alkyl 1,4-dihydro-2,6-dimethyl-4-(1- methyl-5-nitro-2-imidazolyl)-3, 5-pyridinedicarboxylates. Farmaco. (2002) 57: 123-8.
9. Nekooeian AA and Mashhoodi T. Solid plexiglas clips to induce reproducible renal hypertension in the rat. Ind. J. Pharmcol. (2007) 39: 25-6.
10. Hypercube Inc., Hyperchem Software, Version 7, Available from:http://www.hyper.com.
11. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, other names. Gaussian 98, Revision A.7. Pittsburgh, PA: Gaussian, Inc. (1998).
12. Miri R, Javidnia K, Sarkarzadeh H and Hemmateenejad B. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1, 4-dihydropyridines as calcium channel antagonist. Bioorg. Med. Chem. (2006) 15: 4842-9.